

# Datasheet: MCA1642FT

**BATCH NUMBER 1804**

<b>Description:</b>	RAT ANTI HUMAN CD52:FITC
<b>Specificity:</b>	CD52
<b>Other names:</b>	CAMPATH-1
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	YTH34.5
<b>Isotype:</b>	IgG2b
<b>Quantity:</b>	25 µg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Species Cross Reactivity	Reacts with: Rhesus Monkey <b>N.B.</b> Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.		
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	FITC	490	525
Preparation	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant		

<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide 1% Bovine Serum Albumin
<b>Approx. Protein Concentrations</b>	IgG concentration 0.1 mg/ml
<b>Immunogen</b>	Human lymphocytes
<b>External Database Links</b>	<p><b>UniProt:</b>  <a href="#">P31358</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">1043</a>    CD52    <a href="#">Related reagents</a></p>
<b>Synonyms</b>	CDW52, HE5
<b>RRID</b>	AB_2075608
<b>Specificity</b>	<p><b>Rat anti Human CD52 antibody, clone YTH34.5</b> recognizes the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (<a href="#">Xia <i>et al.</i> 1991</a>).</p> <p>The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment (<a href="#">Rowan <i>et al.</i> 1998</a>).</p> <p>CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.</p> <p>Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (<a href="#">Dearden <i>et al.</i> 2002</a>; <a href="#">Pettitt <i>et al.</i> 2012</a>).</p>
<b>Flow Cytometry</b>	Use 10ul of the suggested working dilution to label 1 x 10 <sup>6</sup> cells in 100ul.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Klangsinsirikul, P. <i>et al.</i> (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. <a href="#">Blood. 99: 2586-91.</a></li> <li>2. Ratzinger, G. <i>et al.</i> (2003) Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. <a href="#">Blood. 101: 1422-9.</a></li> <li>3. Zand, M.S. <i>et al.</i> (2005) A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity. <a href="#">Am J Transplant. 5: 76-86.</a></li> <li>4. Westermann, J <i>et al.</i> (2005) CD52 Is Not a Promising Immunotherapy Target for Most</li> </ol>

- Patients with Multiple Myeloma [International Journal of Hematology. 82 \(3\): 248-50.](#)
5. Gopcsa, L. *et al.* (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells. [Eur J Haematol. 75: 346-51.](#)
  6. Rodig SJ *et al.* (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). [Clin Cancer Res. 12 \(23\): 7174-9.](#)
  7. Golay, J. *et al.* (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. [Haematologica. 91: 322-30.](#)
  8. Miles, R.R. *et al.* (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. [Br J Haematol. 138: 506-12.](#)
  9. Chang, S.T. *et al.* (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas. [Leuk Lymphoma. 48: 117-21.](#)
  10. Piccaluga, P.P. *et al.* (2007) Expression of CD52 in peripheral T-cell lymphoma. [Haematologica. 92: 566-7.](#)
  11. Reimer, P. *et al.* (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. [J Clin Oncol. 27: 106-13.](#)
  12. Hu, Y. *et al.* (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. [Immunology. 128: 260-70.](#)
  13. Rizzo, K. *et al.* (2009) Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation. [Cytometry B Clin Cytom. 76: 142-9.](#)
  14. Haniffa, M. *et al.* (2009) Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. [J Exp Med. 206: 371-85.](#)
  15. Bisig, B. *et al.* (2013) CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. [Haematologica. 98 \(8\): 1250-8.](#)
  16. Paulus, A. *et al.* (2015) Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications. [PLoS One. 10 \(4\): e0122338.](#)
  17. Hotta, R. *et al.* (2016) CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment. [PLoS One. 11 \(8\): e0161618.](#)
  18. Buckstein, R. *et al.* (2016) Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. [Clin Lymphoma Myeloma Leuk. 16 \(1\): 18-28.e4.](#)
  19. Craig, J.W. *et al.* (2018) Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. [PLoS One. 13 \(7\): e0199708.](#)

---

#### Further Reading

1. Salisbury JR *et al.* (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. [J Clin Pathol. 47 \(4\): 313-7.](#)
  2. Hale G *et al.* (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. [Blood. 92 \(12\): 4581-90.](#)
- 

#### Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

<b>Guarantee</b>	12 months from date of despatch
------------------	---------------------------------

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10041 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1642FT">https://www.bio-rad-antibodies.com/SDS/MCA1642FT</a> 10041
--------------------------------------	--

---

<b>Regulatory</b>	For research purposes only
-------------------	----------------------------

---

## Related Products

### Recommended Negative Controls

[RAT IgG2b NEGATIVE CONTROL:FITC \(MCA6006F\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South America** Tel: +1 800 265 7376  
Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)  
'M365558:200529'

**Printed on 01 May 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)